These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31182369)

  • 1. Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis.
    Drevinek P; Pressler T; Cipolli M; De Boeck K; Schwarz C; Bouisset F; Boff M; Henig N; Paquette-Lamontagne N; Montgomery S; Perquin J; Tomkinson N; den Hollander W; Elborn JS
    J Cyst Fibros; 2020 Jan; 19(1):99-107. PubMed ID: 31182369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.
    Sermet-Gaudelus I; Clancy JP; Nichols DP; Nick JA; De Boeck K; Solomon GM; Mall MA; Bolognese J; Bouisset F; den Hollander W; Paquette-Lamontagne N; Tomkinson N; Henig N; Elborn JS; Rowe SM
    J Cyst Fibros; 2019 Jul; 18(4):536-542. PubMed ID: 30467074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cystic Fibrosis-Like Airway Surface Layer Is not a Significant Barrier for Delivery of Eluforsen to Airway Epithelial Cells.
    Brinks V; Lipinska K; de Jager M; Beumer W; Button B; Livraghi-Butrico A; Henig N; Matthee B
    J Aerosol Med Pulm Drug Deliv; 2019 Oct; 32(5):303-316. PubMed ID: 31120356
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis.
    Beumer W; Swildens J; Leal T; Noel S; Anthonijsz H; van der Horst G; Kuiperij-Boersma H; Potman M; van Putten C; Biasutto P; Platenburg G; de Jonge H; Henig N; Ritsema T
    PLoS One; 2019; 14(6):e0219182. PubMed ID: 31251792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
    Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.
    Walker S; Flume P; McNamara J; Solomon M; Chilvers M; Chmiel J; Harris RS; Haseltine E; Stiles D; Li C; Ahluwalia N; Zhou H; Owen CA; Sawicki G;
    J Cyst Fibros; 2019 Sep; 18(5):708-713. PubMed ID: 31253540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).
    Konstan MW; VanDevanter DR; Rowe SM; Wilschanski M; Kerem E; Sermet-Gaudelus I; DiMango E; Melotti P; McIntosh J; De Boeck K;
    J Cyst Fibros; 2020 Jul; 19(4):595-601. PubMed ID: 31983658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).
    Kazani S; Rowlands DJ; Bottoli I; Milojevic J; Alcantara J; Jones I; Kulmatycki K; Machineni S; Mostovy L; Nicholls I; Nick JA; Rowe SM; Simmonds NJ; Vegesna R; Verheijen J; Danahay H; Gosling M; Ayalavajjala PS; Salman M; Strieter R
    J Cyst Fibros; 2021 Mar; 20(2):250-256. PubMed ID: 33293212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.
    Bell SC; Barry PJ; De Boeck K; Drevinek P; Elborn JS; Plant BJ; Minić P; Van Braeckel E; Verhulst S; Muller K; Kanters D; Bellaire S; de Kock H; Geller DE; Conrath K; Van de Steen O; van der Ent K
    J Cyst Fibros; 2019 Sep; 18(5):700-707. PubMed ID: 31056441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study.
    Nick JA; St Clair C; Jones MC; Lan L; Higgins M;
    J Cyst Fibros; 2020 Jan; 19(1):91-98. PubMed ID: 31784217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
    Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
    Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
    Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
    Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
    Goss CH; Fajac I; Jain R; Seibold W; Gupta A; Hsu MC; Sutharsan S; Davies JC; Mall MA
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34385272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.